RT Journal Article
SR Electronic
T1 Sensitive detection of SARS-CoV-2-specific-antibodies in dried blood spot samples
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.01.20144295
DO 10.1101/2020.07.01.20144295
A1 Morley, Gabriella L.
A1 Taylor, Stephen
A1 Jossi, Sian
A1 Perez-Toledo, Marisol
A1 Faustini, Sian E.
A1 Marcial-Juarez, Edith
A1 Shields, Adrian M.
A1 Goodall, Margaret
A1 Allen, Joel D.
A1 Watanabe, Yasunori
A1 Newby, Maddy L.
A1 Crispin, Max
A1 Drayson, Mark T.
A1 Cunningham, Adam F.
A1 Richter, Alex G.
A1 O’Shea, Matthew K.
YR 2020
UL http://medrxiv.org/content/early/2020/07/02/2020.07.01.20144295.abstract
AB Importance Population-wide serological testing is an essential component in understanding the COVID-19 pandemic. The logistical challenges of undertaking widespread serological testing could be eased through use of a reliable dried blood spot (DBS) sampling method.Objective To validate the use of dried blood spot sampling for the detection of SARS-CoV-2-specific antibodies.Design, setting and participants Eighty-seven matched DBS and serum samples were obtained from eighty individuals, including thirty-one who were previously PCR-positive for SARS-CoV-2. DBS eluates and sera were used in an ELISA to detect antibodies to the viral spike protein.Results Specific anti-SARS-Cov-2 spike glycoprotein antibodies were detectable in both serum and DBS eluate and there was a significant correlation between the antibody levels detected in matched samples (r = 0.96, p<0.0001). Using serum as the gold standard in the assay, matched DBS samples achieved a Cohen’s kappa coefficient of 0.975 (near-perfect agreement), a sensitivity of 98.1% and specificity of 100%, for detecting anti-spike glycoprotein antibodies.Conclusions and relevance Eluates from DBS samples are a reliable and reproducible source of antibodies to be used for the detection of SARS-CoV-2-specific antibodies. The use of DBS sampling could complement the use of venepuncture in the immunosurveillance of COVID-19 in both low and high income settings.Competing Interest StatementST is the Medical Director of the Saving Lives Charity. MTD and MG report stocks in Abingdon Health (outside the submitted work).Funding StatementThis work was carried out within the Clinical Immunology Service Laboratories at the University of Birmingham. This work was supported by the Wellcome Trust and by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the UHB NHS Foundation Trust and the University of Birmingham. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This project was supported by the Saving Lives Charity (UK Charity Commission number 1144855) who kindly provided the TakeATestUK Dried Blood Spot postal collection kits. The work, in the laboratory of Prof. Max Crispin, was funded by the International AIDS Vaccine Initiative, Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (OPP1196345/INV-008813, OPP1084519 and OPP1115782), the Scripps Consortium for HIV Vaccine Development (CHAVD) (NIH: National Institute for Allergy and Infectious Diseases AI144462), and the University of Southampton Coronavirus Response Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the University of Birmingham (reference ERN_16-178) and the University Hospitals NHS Foundation Trust (REC reference 2002/201).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this work are available within the article.